These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
147 related articles for article (PubMed ID: 30629447)
41. Characterization of the immune response elicited by the vaccinia virus L3 protein delivered as naked DNA. Ramírez M; Santos S; Martínez O; Rodríguez R; Miranda E; Ramos-Perez WD; Otero M Vaccine; 2018 Apr; 36(15):2049-2055. PubMed ID: 29525282 [TBL] [Abstract][Full Text] [Related]
42. Palisade structure in intact vaccinia virions. Hernandez-Gonzalez M; Calcraft T; Nans A; Rosenthal PB; Way M mBio; 2024 Feb; 15(2):e0313423. PubMed ID: 38171004 [TBL] [Abstract][Full Text] [Related]
43. Selective modulation of cell surface proteins during vaccinia infection: A resource for identifying viral immune evasion strategies. Depierreux DM; Altenburg AF; Soday L; Fletcher-Etherington A; Antrobus R; Ferguson BJ; Weekes MP; Smith GL PLoS Pathog; 2022 Jun; 18(6):e1010612. PubMed ID: 35727847 [TBL] [Abstract][Full Text] [Related]
44. MHC class II-restricted presentation of endogenously synthesized antigen: Epstein-Barr virus transformed B cell lines can present the viral glycoprotein gp340 by two distinct pathways. Lee SP; Wallace LE; Mackett M; Arrand JR; Searle PF; Rowe M; Rickinson AB Int Immunol; 1993 May; 5(5):451-60. PubMed ID: 8391306 [TBL] [Abstract][Full Text] [Related]
45. Determination of a Predictive Cleavage Motif for Eluted Major Histocompatibility Complex Class II Ligands. Paul S; Karosiene E; Dhanda SK; Jurtz V; Edwards L; Nielsen M; Sette A; Peters B Front Immunol; 2018; 9():1795. PubMed ID: 30127785 [TBL] [Abstract][Full Text] [Related]
46. Antibiotic-dependent expression of early transcription factor subunits leads to stringent control of vaccinia virus replication. Hagen CJ; Titong A; Sarnoski EA; Verardi PH Virus Res; 2014 Mar; 181():43-52. PubMed ID: 24394294 [TBL] [Abstract][Full Text] [Related]
48. Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine. Tsang KY; Zaremba S; Nieroda CA; Zhu MZ; Hamilton JM; Schlom J J Natl Cancer Inst; 1995 Jul; 87(13):982-90. PubMed ID: 7629885 [TBL] [Abstract][Full Text] [Related]
49. Discovering naturally processed antigenic determinants that confer protective T cell immunity. Gilchuk P; Spencer CT; Conant SB; Hill T; Gray JJ; Niu X; Zheng M; Erickson JJ; Boyd KL; McAfee KJ; Oseroff C; Hadrup SR; Bennink JR; Hildebrand W; Edwards KM; Crowe JE; Williams JV; Buus S; Sette A; Schumacher TN; Link AJ; Joyce S J Clin Invest; 2013 May; 123(5):1976-87. PubMed ID: 23543059 [TBL] [Abstract][Full Text] [Related]
50. HLA-A2-restricted human CD8(+) cytotoxic T lymphocyte responses to a novel epitope in vaccinia virus that is conserved among orthopox viruses. Dong Y; Denny TN J Infect Dis; 2006 Jul; 194(2):168-75. PubMed ID: 16779722 [TBL] [Abstract][Full Text] [Related]
51. Pox proteomics: mass spectrometry analysis and identification of Vaccinia virion proteins. Yoder JD; Chen TS; Gagnier CR; Vemulapalli S; Maier CS; Hruby DE Virol J; 2006 Mar; 3():10. PubMed ID: 16509968 [TBL] [Abstract][Full Text] [Related]
52. Mass spectrometry and peptide-based vaccine development. Ovsyannikova IG; Johnson KL; Bergen HR; Poland GA Clin Pharmacol Ther; 2007 Dec; 82(6):644-52. PubMed ID: 17971823 [TBL] [Abstract][Full Text] [Related]
53. Generation and characterization of a large panel of murine monoclonal antibodies against vaccinia virus. Meng X; Zhong Y; Embry A; Yan B; Lu S; Zhong G; Xiang Y Virology; 2011 Jan; 409(2):271-9. PubMed ID: 21056889 [TBL] [Abstract][Full Text] [Related]
54. Vaccinia Virus Activation and Antagonism of Cytosolic DNA Sensing. El-Jesr M; Teir M; Maluquer de Motes C Front Immunol; 2020; 11():568412. PubMed ID: 33117352 [TBL] [Abstract][Full Text] [Related]
55. Accurate mass precursor ion data and tandem mass spectrometry identify a class I human leukocyte antigen A*0201-presented peptide originating from vaccinia virus. Johnson KL; Ovsyannikova IG; Madden BJ; Poland GA; Muddiman DC J Am Soc Mass Spectrom; 2005 Nov; 16(11):1812-7. PubMed ID: 16185891 [TBL] [Abstract][Full Text] [Related]
56. Analysis of MHC Class I Processing Pathways That Generate a Response to Vaccinia Virus Late Proteins. Niu TK; Princiotta MF; Sei JJ; Norbury CC Immunohorizons; 2019 Dec; 3(12):559-572. PubMed ID: 31791977 [TBL] [Abstract][Full Text] [Related]
57. Cell surface expression of the vaccinia virus complement control protein is mediated by interaction with the viral A56 protein and protects infected cells from complement attack. Girgis NM; Dehaven BC; Fan X; Viner KM; Shamim M; Isaacs SN J Virol; 2008 May; 82(9):4205-14. PubMed ID: 18287241 [TBL] [Abstract][Full Text] [Related]
58. Inhibition of the MHC class II antigen presentation pathway by human cytomegalovirus. Johnson DC; Hegde NR Curr Top Microbiol Immunol; 2002; 269():101-15. PubMed ID: 12224504 [TBL] [Abstract][Full Text] [Related]
59. Interaction of poxvirus intracellular mature virion proteins with the TPR domain of kinesin light chain in live infected cells revealed by two-photon-induced fluorescence resonance energy transfer fluorescence lifetime imaging microscopy. Jeshtadi A; Burgos P; Stubbs CD; Parker AW; King LA; Skinner MA; Botchway SW J Virol; 2010 Dec; 84(24):12886-94. PubMed ID: 20943972 [TBL] [Abstract][Full Text] [Related]
60. The crystal structure of vaccinia virus protein E2 and perspectives on the prediction of novel viral protein folds. Gao WND; Gao C; Deane JE; Carpentier DCJ; Smith GL; Graham SC J Gen Virol; 2022 Jan; 103(1):. PubMed ID: 35020582 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]